- Investigating Candidate Plant Bioactive & Psychedelic Compounds in Addressing Neurological Disorders.
- Experienced Scientific Team with Successful Track Record
- Santiago Ferro, over 20 years’ experience in pharmaceuticals, biologicals and biotech industries
- Rigorous Data Analysis & Mapping: How Candidate Psychedelics, and Plant Bioactives Affect Neurological Disorders
- DMT-based candidates target Stroke and Parkinson’s Disease
- Psilocybin-based candidate to target Alzheimer’s Disease
- Ketamine-based candidate to target Depression
- Interpretations Warranting Patent Protection.
- 4 provisional patents filed with the United States Patent and Trademark Office:
- 2 DMT-based
- 1 Psilocybin-based
- 1 Ketamine-based
- Engagement of Contract Research Organizations for Development of Clinical Trials
- Universitat de Barcelona, Faculty of Pharmacy and Food Sciences, Laboratory of Medicinal Chemistry
- Commenced Initial in vitro studies to prove out patent claims
